Advances in Understanding Metabolic Diseases through Bioactive Compounds Research

Researchers at the University Hospital Miguel Servet in Spain have made significant contributions to the field of metabolic diseases by investigating the effects of bioactive compounds on conditions such as obesity, diabetes, and liver steatosis. A recent publication in the Journal of Physiology and Biochemistry highlights the importance of preclinical models in studying these effects, emphasizing the need for innovative and robust methods to understand the mechanisms of action. The research also touches on the limitations of current methodologies and the potential for combining and developing new methods to further progress in this field.

Key Takeaways:

• The study highlights the significance of preclinical models in understanding the effects of bioactive compounds on metabolic diseases, with a focus on obesity, diabetes, and liver steatosis.
• In vitro models, such as enzyme assays and standard two-dimensional cultures of adipocytes and skeletal muscle cells, are well-established and widely used methods to study bioactive compounds in metabolic diseases.
• Novel models, such as three-dimensional cultures (spheroids, organoids), are emerging and complementing traditional culture systems, offering a more comprehensive understanding of metabolic diseases.
• Models of small organisms (C. elegans, D. melanogaster) and non-mammal vertebrates (D. rerio) represent a scientific advantage and a middle-step before traditional mammalian models (rats and mice).
• Combining and developing new methods will be key for future progression on the effects of bioactive compounds on metabolic diseases, as well as minimizing the use of mammalian models due to ethical reasons.

Statistics:

• The Journal of Physiology and Biochemistry is a peer-reviewed publication that has been contacting researchers for their studies on metabolic diseases.
• The research team at the University Hospital Miguel Servet consisted of 13 authors, including Marina Clavel-Millan, Paula Aranaz, Katherine Gil-Cardoso, and Jose M. Arbones-Mainar.
• The study mentioned the importance of translating findings from preclinical models to human studies, with the aim of developing more effective treatments for metabolic diseases.

Sources:

• Preclinical research in obesity-associated metabolic diseases using in vitro, multicellular, and non-mammalian models. Journal of Physiology and Biochemistry, 2025.
• Journal of Physiology and Biochemistry can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.
• Marina Clavel-Millan, Adipocyte and Fat Biology Laboratory (AdipoFat), University Hospital Miguel Servet, Zaragoza, 50009, Spain.